SKEL fjárfestingafélag hf.: Advertisement from the Nomination Committee of SKEL on candidacy to the Board of Directors
The Nomination Committee of SKEL fjárfestingafélag hf. hereby advertises for nominations or candidacy to the Board of Directors for The Annual General Meeting of SKEL fjárfestingafélag which will be held on 9 March 2023.
The Nomination Committee has an advisory role regarding the election of Board Members by putting forth a proposal at the AGM. The objective of the Nomination Committee is to establish a transparent and clear procedure for the nomination of Board Members at the Company´s AGM. The procedure is intended to enable the shareholders to take a more informed decision regarding whom to elect for Board membership. The Committees objective is also to ensure that the Company´s Board is sufficiently diverse, when it comes to capabilities, experience and knowledge. Also, that the Board Members´ capabilities are usable for the Company and its subsidiaries.
Board Members must meet the conditions set out in the Company’s articles of association and Article 66 of the Act on Public Limited Liability Companies No. 2/1995. The rules of procedure of the Nomination Committee, the Company’s articles of association and other documents are accessible on SKEL's website.
The Nomination Committee requests that notifications about candidature for the Board of Directors will be submitted, on the attached candidature form, before end of 2 February 2023 at firstname.lastname@example.org. The Committee will invite candidates to meet with them 6-10 February 2023.
The Committee’s proposal will be published, with other proposals to the AGM, 16 February 2023. The Committee reserves the right to change its proposal until 10 days before the AGM. Notification about candidature for the Board of Directors must be submitted five days before the AGM but the Nomination Committee will however not be able to assess candidature that are received within two weeks before the meeting that will be held on 9 March 2023. Information about all candidates will be published on the Company’s website no later than two days before the AGM.
February 2 The Nomination Committee requests that nominations/candidacy are submitted within this day
February 6-10 The Nomination Committee interviews with candidates
February 16 The Nomination Committee submits its report and proposals together with the invite to the AGM
February 23 The Nomination Committee does not assess candidature that is received after 16:00 on this day
February 27 Deadline for the Nomination Committee to change their proposal
March 4 Deadline at 16:00 to submit candidacy for the Board of Directors
March 7 Information about all candidates will be published
March 9 Annual General Meeting of SKEL 2023
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease8.2.2023 22:01:00 CET | Press release
The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints of clinical remission and endoscopic response at Week 58The safety findings were generally consistent with the known profile of filgotinib in rheumatoid arthritis (RA) and ulcerative colitis (UC)Galapagos decided not to submit a Marketing Authorization Application in Europe based on these topline dataGalapagos remains fully committed to filgotinib, a JAK1 preferential inhibitor orally administered once daily, and its approved indications, RA and UC, and is on track to start a Phase 3 trial in axial spondyloarthritis (AxSpA) later this year Mechelen, Belgium; 8February2023, 22:01CET; regulated information; Galapagos NV (Euronext & NASDAQ: GLPG) todayannouncedthe topline results from DIVERSITY,a global Phase 3 trial to evaluate the safety and efficacy of filgotinib,100mg or 200mg once dail
X8 AG Submits a Swiss Fintech Licence Application8.2.2023 21:21:16 CET | Press release
X8 AG submitted the application for a Swiss FinTech license according to Art. 1b Banking Act with the intention of operating a regulated global stablecoin system BAAR, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The X8 AG team has successfully submitted the application to FINMA, the Swiss Financial Market Supervisory Authority, for the Swiss FinTech license according to Article 1b Banking Act. This marks an important step for X8 AG on its way to become a fully regulated global stablecoin system and significantly differentiating itself from the current non-regulated crypto space. Switzerland offers one of the most advanced regulatory frameworks for digital assets. X8 AG believes that designing its stablecoin system under Swiss law is the best starting point to achieve a global X8 cross-border framework for payments. Full compliance with the Swiss regulatory framework strengthens the high standards of protection for clients. X8 AG aims to empower users and their money with frictionles
GN Store Nord announces intention to initiate a rights issue8.2.2023 20:08:16 CET | Press release
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering memorandum or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017. The offer to acquire securities pursuant to the offering is made, and any investor should make their investment decision, solely on the basis of information that is contained in the prospectus to be made generally available in Denmark in connection with the offering. GN Store Nord announces intention to initiate a rights issue In accordance with our announcement on November 11, 2022, GN has conducted a comprehensive review of the appropriate capital structure. In light of the current macroeconomic environment and GN’s leverage, GN announces today that it intends to raise gross proceeds of DKK 7 billion in the first half
Nokia Corporation: Repurchase of own shares on 08.02.20238.2.2023 20:00:00 CET | Press release
Nokia Corporation Stock Exchange Release 8 February 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 08.02.2023 Espoo, Finland – On 8 February 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL282,2294.39CEUX20,3804.39AQEU6,3784.39TQEX5,0134.38Total314,0004.39 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023
Interim report 2022/23 - 15% revenue growth and DKK 145 million operating profit (+25%) for the first half following a challenging second quarter8.2.2023 18:57:07 CET | Press release
ANNOUNCEMENT NO. 234 9 February 2023 Interim report for the first half of 2022/23 15% revenue growth and DKK 145 million operating profit (+25%) for the first half following a challenging second quarter Steen Søndergaard, CEO: “Following a very satisfactory 2021/22 with historically high revenue and operating profit growth rates, revenue for the first half of 2022/23 unfortunately disappointed, despite 15% growth. Second quarter sales of instruments, particularly in the North American market, were challenged by a generally more subdued investment sentiment in our primary business segment, cell-based therapy. Our order intake was mainly impacted by weakened demand from capital-sensitive development companies. On the other hand, we saw continued satisfactory growth in sales of consumables and services. Despite the unfavourable market conditions, our earnings continued to grow. While our market is currently affected by the prevailing macroeconomic environment, we have a strong underlying